Table 1. Distribution of TKRs expression in TMA.
Tumor Biomarker Score | |||||
---|---|---|---|---|---|
HER3 | |||||
FGFR2 | 0 | 1 | 2 | 3 | Total (n) |
0 | 15 | 2 | 0 | 0 | 17 |
1 | 11 | 13 | 18 | 1 | 43 |
2 | 22 | 20 | 22 | 4 | 68 |
3 | 5 | 5 | 10 | 7 | 27 |
Total (n) | 43 | 40 | 50 | 12 | 145 |
MET | |||||
FGFR2 | 0 | 1 | 2 | 3 | Total (n) |
0 | 17 | 0 | 0 | 0 | 17 |
1 | 18 | 11 | 1 | 3 | 33 |
2 | 32 | 26 | 6 | 4 | 68 |
3 | 12 | 9 | 6 | 0 | 27 |
Total (n) | 79 | 46 | 13 | 7 | 145 |
EGFR | |||||
FGFR2 | 0 | 1 | 2 | 3 | Total (n) |
0 | 12 | 5 | 0 | 0 | 17 |
1 | 25 | 8 | 0 | 0 | 33 |
2 | 19 | 18 | 20 | 1 | 58 |
3 | 8 | 12 | 5 | 2 | 27 |
Total (n) | 64 | 43 | 25 | 3 | 145 |
Summary of FGFR2, HER3, EGFR and MET status in gastric cancer tissue microarray (n = 145 primary gastric cancer surgical samples). TKR, tyrosine kinase receptor; TMA, tissue microarray analysis; FGFR2, fibroblast growth factor receptor 2; EGFR, epidermal growth factor receptor; HER3, human epidermal growth factor receptor 3.